OncoCyte Cash from Financing (TTM) Analysis

OncoCyte Corp (OCX)

2.46 0.00 (0.00%) USD | NASDAQ | Apr 24, 16:00

2.46 0.00 (0.00%) Pre-Market: 09:22

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
December 31, 2023	12.19M
September 30, 2023	12.12M
June 30, 2023	11.62M
March 31, 2023	36.13M
December 31, 2022	35.81M
September 30, 2022	35.64M
June 30, 2022	44.38M
March 31, 2022	8.138M
December 31, 2021	78.36M
September 30, 2021	82.13M
June 30, 2021	73.94M
March 31, 2021	85.10M
December 31, 2020	22.80M
September 30, 2020	30.16M
June 30, 2020	29.83M
March 31, 2020	17.54M
December 31, 2019	47.87M

Date	Value
September 30, 2019	36.69M
June 30, 2019	40.00M
March 31, 2019	42.24M
December 31, 2018	12.11M
September 30, 2018	12.37M
June 30, 2018	15.23M
March 31, 2018	13.76M
December 31, 2017	9.968M
September 30, 2017	10.16M
June 30, 2017	14.00M
March 31, 2017	13.82M
December 31, 2016	9.881M
September 30, 2016	9.758M
June 30, 2016	8.395M
March 31, 2016	11.70M
December 31, 2015	11.65M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

8.138M

Minimum

Mar 2022

85.10M

Maximum

Mar 2021

38.97M

Average

35.81M

Median

Dec 2022

Cash from Financing (TTM) Benchmarks